Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome

Abstract

Purpose

The purpose of this study was to evaluate the safety of antithrombotic treatments prescribed during pregnancy in patients with antiphospholipid syndrome (APS).

Methods

This international, multicenter study included two cohorts of patients: a retrospective French cohort and a prospective US cohort (PROMISSE study). Inclusion criteria were (1) APS (Sydney criteria), (2) live pregnancy at 12 weeks of gestation (WG) with (3) follow-up data until six weeks post-partum. According to APS standard of care, patients were treated with aspirin and/or low-molecular weight heparin (LMWH) at prophylactic (pure obstetric APS) or therapeutic doses (history of thrombosis). Major bleeding was defined as abnormal blood loss during the pregnancy and/or post-partum period requiring intervention for hemostasis or transfusion, or during the peripartum period greater than 500 mL and/or requiring surgery or transfusion. Other bleeding events were classified as minor.

Results

Two hundred and sixty-four pregnancies (87 prospectively collected) in 204 patients were included (46% with history of thrombosis, 23% with associated systemic lupus). During pregnancy, treatment included LMWH (n = 253; 96%) or low-dose aspirin (n = 223; 84%), and 215 (81%) patients received both therapies. The live birth rate was 89% and 82% in the retrospective and prospective cohorts, respectively. Adverse pregnancy outcomes occurred in 28% of the retrospective cohort and in 40% of the prospective cohort. No maternal death was observed in either cohort. A combined total of 45 hemorrhagic events (25%) occurred in the retrospective cohort, but major bleeding was reported in only six pregnancies (3%). Neither heparin nor aspirin alone nor combined therapy increased the risk of hemorrhage. We also did not observe an increased rate of bleeding in the case of a short interval between last LMWH (less than 24 hours) or aspirin (less than five days) doses and delivery. Only emergency Caesarean section was significantly associated with an increased risk of bleeding (odds ratio (OR) 5.03 (1.41–17.96); p=.016). In the prospective cohort, only one minor bleeding event was reported (vaginal bleeding).

Conclusion

Our findings support the safety of antithrombotic therapy with aspirin and/or LMWH during pregnancy in high-risk women with APS, and highlight the need for better treatments to improve pregnancy outcomes in APS.

PROMISSE Study ClinicalTrials.gov identifier: NCT00198068.

Keywords

Antiphospholipid syndrome antiphospholipid antibody lupus anticoagulant pregnancy aspirin heparin

Get full access to this article

View all access options for this article.

References

de Jesus

Agmon-Levin

Andrade

Andreoli

Chighizola

Porter

et al.

14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev 2014; 13: 795–813.

Andreoli

Bertsias

Agmon-Levin

Brown

Cervera

Costedoat-Chalumeau

et al.

EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017; 76(3): 476–485.

Farquharson

Quenby

Greaves

. Antiphospholipid syndrome in pregnancy: A randomized, controlled trial of treatment. Obstet Gynecol 2002; 100: 408–413.

Laskin

Spitzer

Clark

Crowther

Ginsberg

Hawker

et al.

Low molecular weight heparin and aspirin for recurrent pregnancy loss: Results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36: 279–287.

van Hoorn

Hague

van Pampus

Bezemer

de Vries

JIP

FRUIT investigators . Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: The FRUIT-RCT. Eur J Obstet Gynecol Reprod Biol 2016; 197: 168–173.

Franklin

Kutteh

. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: Treating a unique APA positive population. Hum Reprod 2002; 17: 2981–2985.

Rai

Cohen

Dave

Regan

. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314(7076): 253–257.

Kutteh

. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584–1589.

Mak

Cheung

Cheak

. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: A meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford) 2010; 49: 281–288.

10.

Bouvier

Cochery-Nouvellon

Lavigne-Lissalde

Mercier

Marchetti

Balducchi

J-P

et al.

Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: The NOH-APS observational study. Blood 2014; 123(3): 404–413.

11.

Miyakis

Lockshin

Atsumi

Branch

Brey

Cervera

et al.

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

12.

Lockshin

Kim

Laskin

Guerra

Branch

Merrill

et al.

Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64: 2311–2318.

13.

Buyon

Kim

Guerra

Laskin

Petri

Lockshin

et al.

Predictors of pregnancy outcomes in patients with lupus: A cohort study. Ann Intern Med 2015; 163(3): 153–163.

14.

Yelnik

Laskin

Porter

Branch

Buyon

Guerra

et al.

Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: Validation of PROMISSE study results. Lupus Sci Med 2016; 3: e000131.

15.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

16.

Van Buuren S, Groothuis-Oudshoorn K. MICE: Multivariate imputation by chained equations in R. J Stat Softw. Epub 12 December 2011. DOI: 10.18637/jss.v045.i03.

17.

Rubin

. Multiple imputation for nonresponse in surveys, New York: John Wiley and Sons, 1987.

18.

Cervera

Piette

J-C

Font

Khamashta

Shoenfeld

Camps

et al.

Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019–1027.

19.

Bramham

Hunt

Germain

Calatayud

Khamashta

Bewley

et al.

Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 2010; 19: 58–64.

20.

Reyal

Deffarges

Luton

Blot

Oury

Sibony

. [Severe post-partum hemorrhage: descriptive study at the Robert-Debré Hospital maternity ward] [article in French]. J Gynécologie Obstétrique Biol Reprod 2002; 31: 358–364.

21.

Deneux-Tharaux

Bonnet

M-P

Tort

. [Epidemiology of post-partum haemorrhage] [article in French]. J Gynecol Obstet Biol Reprod (Paris) 2014; 43: 936–950.

22.

Ayala

Ucieda

Hermida

. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int 2013; 30: 260–279.

23.

CLASP. A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994; 343(8898): 619–629.

24.

Hanouna

Morel

Le Thi Huong

Josselin

Vauthier-Brouzes

Saadoun

et al.

Catastrophic antiphospholipid syndrome and pregnancy: An experience of 13 cases. Rheumatology (Oxford) 2013; 52: 1635–1641.